PRECIGEN, INC. (PGEN) Operating Margin
- Operating margin · 12 months: Value -46.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -46.08% | Operating income / revenue. Period ending 2026-06-30. $-39.50M ÷ $85.72M × 100 ≈ -46.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -39.50M USD | Operating Income (Loss) |
| Revenue | 85.72M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 32.29M USD | Research and Development Expense |
| Selling, general and administration | 84.93M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-39.50M | $85.72M | (m) | $32.29M | $84.93M | -46.08% |
| 2026-03-31 | $-93.91M | $31.59M | (m) | $36.49M | $78.82M | -297.21% |
| 2025-12-31 | $-110.51M | $9.68M | (m) | $41.33M | $70.13M | -1141.13% |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-135.03M | $3.92M | (m) | $53.07M | $41.29M | -3440.23% |
| 2023-12-31 | $-99.76M | $6.22M | (m) | $48.61M | $40.41M | -1602.54% |
| 2023-06-30 | (m) | $22.10M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $23.25M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.91M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $118.44M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $105.05M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $111.38M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $103.87M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $98.98M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $101.01M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $97.85M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-86.60M | $103.18M | (m) | (m) | (m) | -83.94% |
| 2020-09-30 | (m) | $100.85M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $95.56M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $97.97M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-204.21M | $90.72M | (m) | (m) | (m) | -225.10% |
| 2019-09-30 | $-481.61M | $125.55M | (m) | $379.57M | $104.75M | -383.60% |
| 2019-06-30 | $-499.46M | $134.95M | (m) | $392.98M | $118.72M | -370.10% |
| 2019-03-31 | $-511.66M | $144.24M | (m) | $400.38M | $131.66M | -354.72% |
| 2018-12-31 | $-505.61M | $160.57M | (m) | $404.59M | $137.81M | -314.88% |
| 2018-09-30 | $-195.22M | $194.42M | (m) | $162.62M | $145.72M | -100.41% |
| 2018-06-30 | $-173.50M | $207.99M | (m) | $154.20M | $146.29M | -83.42% |
| 2018-03-31 | $-154.98M | $221.08M | (m) | $146.29M | $150.70M | -70.10% |
| 2017-12-31 | $-137.89M | $230.98M | (m) | $143.21M | $146.10M | -59.70% |
| 2017-09-30 | $-143.99M | $199.96M | (m) | $133.53M | $148.62M | -72.01% |
| 2017-06-30 | $-128.06M | $202.92M | (m) | $126.09M | $143.16M | -63.11% |
| 2017-03-31 | $-116.01M | $201.24M | (m) | $120.46M | $134.57M | -57.65% |
| 2016-12-31 | $-125.17M | $190.93M | (m) | $112.14M | $142.32M | -65.56% |
| 2016-09-30 | $-126.97M | $186.42M | (m) | $109.46M | $141.69M | -68.11% |
| 2016-06-30 | $-106.07M | $190.80M | (m) | $102.03M | $130.90M | -55.59% |
| 2016-03-31 | $-100.27M | $183.19M | (m) | $94.03M | $124.31M | -54.74% |
| 2015-12-31 | $-146.86M | $173.60M | (m) | $147.48M | $109.06M | -84.60% |
| 2015-09-30 | $-131.43M | $163.20M | (m) | $138.93M | $94.10M | -80.53% |
| 2015-06-30 | $-138.56M | $131.03M | (m) | $132.18M | $85.93M | -105.75% |
| 2015-03-31 | $-139.21M | $97.92M | (m) | $126.23M | $77.64M | -142.16% |
| 2014-12-31 | $-69.96M | $71.93M | (m) | $58.98M | $63.65M | -97.26% |
| 2014-09-30 | $-68.73M | $47.98M | (m) | $53.91M | (m) | -143.24% |
| 2014-06-30 | $-65.72M | $32.83M | (m) | $49.81M | (m) | -200.20% |
| 2014-03-31 | $-61.89M | $27.73M | (m) | $48.84M | (m) | -223.19% |
| 2013-12-31 | $-58.02M | $23.76M | (m) | $48.16M | (m) | -244.20% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-64.04M | $16.09M | (m) | (m) | (m) | -397.90% |
| 2012-12-31 | $-75.16M | $13.77M | (m) | $64.03M | (m) | -545.64% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-82.43M | $8.01M | (m) | $70.23M | (m) | -1028.67% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |